Christoph A. Gebeshuber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christoph A. Gebeshuber has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Javier Martinez
Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria
1 shared publication Kurt Zatloukal
Institute for Pathology, Medical University of Graz Auenbruggerplatz 25 Graz Austria
1 shared publication- Stefan Grünert
Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria
1 shared publication Stefan Sladecek
1 shared publication
Latest Publications
- Open Access
- 27 February 2009
- Published by Springer Nature in EMBO Reports
- Vol. 10 (4) , 400-405
miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 27 February 2009
- Published by Springer Nature in EMBO Reports
- Vol. 10 (4) , 400-405
Open AccessmiR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 1 June 2007
- Published by S. Karger AG in Cells Tissues Organs
- Vol. 185 (1-3) , 51-60
β-Catenin/LEF-1 Signalling in Breast Cancer – Central Players Activated by a Plethora of Inputs
Although the role of Wnt signalling in breast cancer is far from being fully understood, in the last years its importance has been reported frequently. Besides stimulation by canonical Wnt signalling, the downstream effectors β-catenin and the transcriptional modulators of the T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) family can also be activated by other inputs including the TGF-β pathway. Wnt and TGF-β signalling are both major signal transduction pathways, which provide important cues during development and tumor progression. However, particularly TGF-β has a complicated influence on oncogenesis, which ranges from suppressive to promoting activity. Signalling pathways activated in parallel with TGF-β might determine the oncogenic influence, and therefore place signals cooperating with TGF-β into the limelight. During early development Wnt and TGF-β signalling collaborate extensively. Here we provide an overview of the known interactions of Wnt with TGF-β signalling in development and metastasis, particularly in breast cancer. We want to focus on the Wnt-activated transcription factor complex β-catenin/LEF-1, its upstream activators, its downstream targets and consequences on the cellular level in response to β-catenin/LEF-1 activation.
- 1 June 2007
- Published by S. Karger AG in Cells Tissues Organs
- Vol. 185 (1-3) , 51-60
β-Catenin/LEF-1 Signalling in Breast Cancer – Central Players Activated by a Plethora of Inputs
Although the role of Wnt signalling in breast cancer is far from being fully understood, in the last years its importance has been reported frequently. Besides stimulation by canonical Wnt signalling, the downstream effectors β-catenin and the transcriptional modulators of the T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) family can also be activated by other inputs including the TGF-β pathway. Wnt and TGF-β signalling are both major signal transduction pathways, which provide important cues during development and tumor progression. However, particularly TGF-β has a complicated influence on oncogenesis, which ranges from suppressive to promoting activity. Signalling pathways activated in parallel with TGF-β might determine the oncogenic influence, and therefore place signals cooperating with TGF-β into the limelight. During early development Wnt and TGF-β signalling collaborate extensively. Here we provide an overview of the known interactions of Wnt with TGF-β signalling in development and metastasis, particularly in breast cancer. We want to focus on the Wnt-activated transcription factor complex β-catenin/LEF-1, its upstream activators, its downstream targets and consequences on the cellular level in response to β-catenin/LEF-1 activation.